Transcriptomic sequencing for DTPs

NIAID Data Ecosystem2026-05-02 收录

药物耐受持久细胞

耐药机制转录组分析

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP486366 数据链接链接失效反馈

官方服务：

资源简介：

Four paired DTPs vs Parental cells were sequenced to investigate their gene expression patterns (PC9, A375, GTL-16 and H358). DTP-PC9 were also sequenced with/without treatment of NEO2734 to investigate potential mechanism involved.

创建时间：

2025-08-31

The Ontogeny and Vulnerabilities of Lapatinib Drug Tolerant Persisters [NPY1R]

化疗耐药机制

药物耐受持久细胞

Despite significant advances in HER2-targeted therapies, therapeutic resistance in HER2-positive (HER2+) breast cancer remains a significant clinical problem, especially in the metastatic setting. “Dr

NIAID Data Ecosystem90

Colorectal cancer cells possess an equipotent capacity to enter a reversible diapause-like state to survive chemotherapy

结直肠癌化疗耐药

药物耐受持久细胞

Cancer cells enter a reversible drug tolerant persister (DTP) state to evade death from chemotherapies and targeted agents. It is increasingly appreciated that DTPs are an important driver of therapy

NIAID Data Ecosystem40

Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma

肿瘤内异质性

药物耐受持久细胞

Acquired drug resistance is the major therapeutic obstacle to maintenance treatment of advanced-stage non-small cell lung cancer. Lung adenocarcinoma (ADC) harboring driver mutations also showed poor

NIAID Data Ecosystem20

The Ontogeny and Vulnerabilities of Lapatinib Drug Tolerant Persisters [Parental (P) vs. Drug-Tolerant Persister (DTP)]

HER2靶向治疗耐药

药物耐受持久细胞

Despite significant advances in HER2-targeted therapies, therapeutic resistance in HER2-positive (HER2+) breast cancer remains a significant clinical problem, especially in the metastatic setting. â

NIAID Data Ecosystem50

Drug tolerant persisters in erlotinib treated EGFR-mutated lung adenocarcinoma arise from pre-existing tumor cells and survive in an adapted stromal microenvironment [RNA-seq]. Drug tolerant persisters in erlotinib treated EGFR-mutated lung adenocarcinoma arise from pre-existing tumor cells and survive in an adapted stromal microenvironment [RNA-seq]

肺癌靶向耐药机制

药物耐受持久细胞

Targeted therapies require life-long treatment, as drug discontinuation invariably leads to tumor recurrence. Recurrence is thought to mainly be driven by minor subpopulations of drug tolerant persist

NIAID Data Ecosystem30

Transcriptomic sequencing for DTPs

资源简介：

相关数据集